SFStephen S. G. Ferguson

Stephen S. G. Ferguson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stephen S. G. Ferguson has a total of 90 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    β-Arrestin2 Drives Sex-Specific Akt/GSK3β Signaling, Aβ Pathology, and Cognitive Decline in Alzheimer’s Disease Mice

    by Fatemeh A. Panahi, Fatemeh Babaei, Tash-Lynn L. Colson, Stephen S. G. Ferguson

    Sex is a major determinant of Alzheimer’s disease risk and progression, yet the molecular mechanisms underlying this dimorphism remain poorly defined, limiting the development of sex-informed therapeutics. β-Arrestin2 is a pervasive, multifunctional regulator common to a host of G protein-coupled receptors (GPCRs) in the brain, but whether it has a sex-dependent role in Alzheimer’s disease is unknown. Here, we demonstrate that β-arrestin2 deficiency produces sexually dimorphic effects on Aβ pathology, neuroinflammation, cognition and autophagic flux in APPswe/PS1ΔE9 (APP/PS1) mice. In males, Arrb2 deletion reduced Aβ oligomer burden, enhanced autophagy, suppressed astrocytic and microglial reactivity, and broadly rescued cognition encompassing spatial working memory, spatial learning, cognitive flexibility, and recognition memory. In females, Aβ pathology and astrogliosis was unchanged and microgliosis was enhanced, with cognitive improvement limited to recognition memory. The male-specific reduction in pathology was accompanied by decreased S473-Akt and S9-GSK3β phosphorylation and enhanced GSK3β/ZBTB16-mediated autophagy, identifying β-arrestin2 as a molecular switch driving sex-restricted Aβ pathology, glial activation, and cognitive decline in male APP/PS1 mice. These findings identify β- arrestin2 as a sex-dependent node linking Aβ pathology to cognitive outcomes in males but not females, underscoring the necessity of sex-stratified consideration in the design of GPCR-targeted Alzheimer’s disease therapeutics.

  • Open Access

    TRIM9 Determines Sex-Specific β-Amyloid/Cellular Prion Protein/mGluR5 Complex Formation and Pathological Signaling in Alzheimer’s Disease Mice

    by Fatemeh Babaei, Fatemeh A. Panahi, Tash-Lynn L. Colson, Hang Cheng, Mario Tiberi, Rony Chidiac, Stephane Anger, Stephanie L. Gupton, Khaled S. Abd-Elrahman, Stephen S. G. Ferguson

    Biological sex is a major determinant of Alzheimer’s disease prevalence, yet the molecular mechanisms underlying sex-specific vulnerability remain largely unknown. Metabotropic glutamate receptor 5 (mGluR5) functions as a co-receptor for β-amyloid (Aβ42) oligomer/cellular prion protein (PrP C )-mediated pathogenic signaling in males but not females, establishing a sex-dimorphic node in β-amyloid pathophysiology whose regulatory basis is undefined. Using quantitative proteomic analysis, we identify the E3 ubiquitin ligase TRIM9 as a novel mGluR5-interacting protein and a previously unrecognized sex-specific regulator of the Aβ42/PrP C /mGluR5 complex. TRIM9 selectively associates with mGluR5 in male but not female APP/PS1 mouse brain and is required for mGluR5 to serve as a co-receptor for PrP C -dependent Aβ42 oligomer binding. Genetic deletion of TRIM9 abolishes Aβ42/PrP C /mGluR5 complex assembly in male APP/PS1 mice demonstrating that TRIM9 is an essential scaffold for male-specific Aβ42 signal transduction. Loss of TRIM9 in males further reduces β-amyloid pathology by restoring Akt/GSK3β/ZBTB16-dependent autophagic flux, linking disruption of this complex to a defined downstream proteostatic mechanism. Together, these findings establish TRIM9 as a critical molecular determinant coupling male-specific Aβ42/PrP C /mGluR5 complex assembly to downstream neurodegenerative signaling and β-amyloid pathology. They reveal an unappreciated layer of sex-dependent complexity in mGluR5 pharmacology and identify disruption of the TRIM9/mGluR5 interaction as a potential male-specific therapeutic strategy for Alzheimer’s disease. Significance Statement: The molecular basis of sex differences in Alzheimer’s disease vulnerability remains unresolved. We show that mGluR5 functions as a male-specific co-receptor for pathogenic Aβ42/PrP C signaling and identify the E3 ubiquitin ligase TRIM9 as the factor governing this dimorphism. TRIM9 selectively assembles the Aβ42/PrP C /mGluR5 complex in male brain, and its genetic deletion disrupts complex formation while restoring Akt/GSK3β-dependent autophagic clearance of amyloid. These findings define a sex-specific signaling axis underlying β-amyloid pathogenesis and establish TRIM9 as a candidate target for sex-informed Alzheimer’s therapeutics.

  • Open Access

    Blocking estrogen receptors restores surface mGluR5 but not downstream signaling in female APP/PS1 Mice

    by Karim S. Ibrahim, Awatif Albaker, Khaled S. Abd-Elrahman, Stephen S. G. Ferguson

    Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that disproportionately affects women. Deposition of β-amyloid (Aβ), a hallmark of AD pathology, disrupts metabotropic glutamate receptor-5 (mGluR5) regulation of autophagy and accelerates disease progression in male AD mouse models. Yet, mGluR5 contribution to Aβ pathology is not observed in female AD mice, suggesting a distinct sex-selective profile. Given that estrogen receptors (ERs) form functional complexes with mGluR5 selectively in females, we assessed the role of ER activity in mGluR5 expression and downstream signaling in APPswe/PS1ΔE9 (APP/PS1) mice. We report here that mGluR5 cell surface expression is elevated in male but reduced in female APP/PS1 cortex relative to sex-matched wildtype controls, with total receptor expression remaining unchanged in both sexes. Treatment with the ER blocker, ICI 182,780, restored mGluR5 cell surface expression in female APP/PS1 mice but failed to rescue GSK3β and ULK1-regulated autophagy signaling. These findings indicate that male and female mGluR5 are embedded within intrinsically distinct signaling interactomes that are independent of ER regulation.


  • Membrane Proteome Remodeling in Female APP/PS1 Mice Following M1 Muscarinic Receptor Modulation Revealed by Peptidisc-Enabled DIA-MS

    by Ashim Bhattacharya, Frank Antony, Hiroyuki Aoki, Mohan Babu, Stephen S. G. Ferguson, Khaled S. Abd-Elrahman, Franck Duong van Hoa

    Alzheimer’s disease (AD) is associated with dysregulation of membrane proteins controlling amyloid processing, synaptic signaling, and neuronal communication, yet most proteomic studies focus on soluble fractions, limiting insight into membrane-centered pathology. Here, we apply a membrane-mimetic, data-independent acquisition workflow to define disease- and drug-induced remodeling of the cortical membrane proteome in an APP mouse model of AD. Female wildtype B6C3F1/J and APP/PS1 mice were aged to 9 months, treated ± the M1 positive allosteric modulator VU0486846, and validated by enrichment of APP in cortical membranes of APP/PS1 mice. This confirmed pathological context enabled direct interrogation of membrane remodeling, revealing pronounced, genotype-specific changes characterized by selective enrichment of AD-linked membrane proteins including RyR2, PLD3, ITM2C, and CNTNAP2, alongside broader shifts in pathways related to calcium signaling, synaptic organization, and membrane trafficking. In contrast, wildtype membranes were enriched in proteins associated with axon guidance and synaptic structure, such as EPHA5 and ROBO2. M1 activation produced minimal changes in wildtype mice but selectively enhanced proteins linked to neuronal trafficking and synaptic plasticity in APP/PS1 mice, including SORCS2, PLXND1, and CADM1, indicating preferential engagement of disease-altered pathways. These findings demonstrate that AD-associated remodeling is concentrated at the membrane level and highlight Peptidisc-enabled membrane proteomics as a powerful approach to resolve disease mechanisms and therapeutic target engagement.


  • Open Access

    Comparison of Huntington’s disease phenotype progression in male and female heterozygous FDNQ175 mice

    by Si Han Li, Tash-Lynn L. Colson, Jingwei Chen, Khaled S. Abd-Elrahman, Stephen S. G. Ferguson

    Huntington’s Disease (HD) is an inherited autosomal dominant neurodegenerative disorder that leads to progressive motor and cognitive impairment due to the expansion of a polyglutamine (CAG) repeat in the N-terminal region of the huntingtin (Htt) protein. The creation of HD mouse models represents a critical step in the research for HD treatment. Among the currently available HD mouse models, the zQ175 knock-in mouse line is the first to display robust disease phenotype on a heterozygous background. The newer FDNQ175 mouse model is derived from the zQ175 mouse line and presents a more aggressive phenotype. Moreover, increasing evidence has implicated sex as a contributing factor in the progression of HD symptoms. Here, we compared the progression of HD phenotypes in male and female heterozygous FDNQ175 mice. We found that both male and female heterozygous mice showed deficits in forelimb grip strength and cognition as early as 6 months of age. However, female FDNQ175 mice were less vulnerable to HD-associated decline in limb coordination and movement. Neither male nor female FDNQ175 mice exhibited reduced locomotor activity in the open field or exhibit consistent differences in anxiety at 6–12 months of age. Both male and female FDNQ175 mice exhibited increased numbers of huntingtin aggregates with age and 8-month-old female FDNQ175 mice had significantly more aggregates than their male counterparts. Taken together, our results provide further evidence that sex can influence the progression of HD phenotype in preclinical animal models and must be taken into consideration for future HD research.


  • Open Access

    VGLUT3 Deletion Rescues Motor Deficits and Neuronal Loss in the zQ175 Mouse Model of Huntington's Disease

    by Karim S. Ibrahim, Salah El Mestikawy, Khaled S. Abd-Elrahman, Stephen S.G. Ferguson

    Huntington's disease (HD) is an autosomal-dominant neurodegenerative disease characterized by progressive motor and cognitive impairments, with no disease-modifying therapies yet available. HD pathophysiology involves evident impairment in glutamatergic neurotransmission leading to severe striatal neurodegeneration. The vesicular glutamate transporter-3 (VGLUT3) regulates the striatal network that is centrally affected by HD. Nevertheless, current evidence on the role of VGLUT3 in HD pathophysiology is lacking. Here, we crossed mice lacking Slc17a8 gene ( VGLUT3 –/– ) with heterozygous zQ175 knock-in mouse model of HD ( zQ175:VGLUT3 –/– ). Longitudinal assessment of motor and cognitive functions from 6 to 15 months of age reveals that VGLUT3 deletion rescues motor coordination and short-term memory deficits in both male and female zQ175 mice. VGLUT3 deletion also rescues neuronal loss likely via the activation of Akt and ERK1/2 in the striatum of zQ175 mice of both sexes. Interestingly, the rescue in neuronal survival in zQ175:VGLUT3 –/– mice is accompanied by a reduction in the number of nuclear mutant huntingtin (mHTT) aggregates with no change in the total aggregate levels or microgliosis. Collectively, these findings provide novel evidence that VGLUT3, despite its limited expression, can be a vital contributor to HD pathophysiology and a viable target for HD therapeutics. SIGNIFICANCE STATEMENT Dysregulation of the striatal network centrally contributes to the pathophysiology of Huntington's disease (HD). The atypical vesicular glutamate transporter-3 (VGLUT3) has been shown to regulate several major striatal pathologies, such as addiction, eating disorders, or L-DOPA-induced dyskinesia. Yet, our understanding of VGLUT3's role in HD remains unclear. We report here that deletion of the Slc17a8 ( Vglut3 ) gene rescues the deficits in both motor and cognitive functions in HD mice of both sexes. We also find that VGLUT3 deletion activates neuronal survival signaling and reduces nuclear aggregation of abnormal huntingtin proteins and striatal neuron loss in HD mice. Our novel findings highlight the vital contribution of VGLUT3 in HD pathophysiology that can be exploited for HD therapeutic management.


  • Open Access

    The Role of Neuroglial Metabotropic Glutamate Receptors in Alzheimer’s Disease

    by Khaled S. Abd-Elrahman, Shaarika Sarasija, Stephen S.G. Ferguson

    : Glutamate, the major excitatory neurotransmitter in the brain exerts its effects via both ionotropic glutamate receptors and metabotropic glutamate receptors (mGluRs). There are three subgroups of mGluRs, pre-synaptic Group II and Group III mGluRs and post-synaptic Group I mGluRs. mGluRs are ubiquitously expressed in the brain and their activation is poised upstream of a myriad of signaling pathways, resulting in their implication in the pathogenesis of various neurodegenerative diseases including, Alzheimer’s Disease (AD). While the exact mechanism of AD etiology remains elusive, β-amyloid (Aβ) plaques and hyperphosphorylated tau tangles remain the histopathological hallmarks of AD. Though less electrically excitable, neuroglia are a major non-neuronal cell type in the brain and are composed of astrocytes, microglia, and oligodendrocytes. Astrocytes, microglia, and oligodendrocytes provide structural and metabolic support, active immune defence, and axonal support and sheathing, respectively. Interestingly, Aβ and hyperphosphorylated tau are known to disrupt the neuroglial homeostasis in the brain, pushing them towards a more neurotoxic state. In this review, we discuss what is currently known regarding the expression patterns of various mGluRs in neuroglia and how Aβ and tau alter the normal mGluR function in the neuroglia and contribute to the pathophysiology of AD.


  • Open Access

    VGLUT3 Ablation Differentially Modulates Glutamate Receptor Densities in Mouse Brain

    by Karim S. Ibrahim, Salah El Mestikawy, Khaled S. Abd-Elrahman, Stephen S.G. Ferguson

    Type 3 vesicular glutamate transporter (VGLUT3) represents a unique modulator of glutamate release from both nonglutamatergic and glutamatergic varicosities within the brain. Despite its limited abundance, VGLUT3 is vital for the regulation of glutamate signaling and, therefore, modulates the activity of various brain microcircuits. However, little is known about how glutamate receptors are regulated by VGLUT3 across different brain regions. Here, we used VGLUT3 constitutive knock-out (VGLUT3–/–) mice and explored how VGLUT3 deletion influences total and cell surface expression of different ionotropic and metabotropic glutamate receptors. VGLUT3 deletion upregulated the overall expression of metabotropic glutamate receptors mGluR5 and mGluR2/3 in the cerebral cortex. In contrast, no change in the total expression of ionotropic NMDAR glutamate receptors were observed in the cerebral cortex of VGLUT3–/–mice. We noted significant reduction in cell surface levels of mGluR5, NMDAR2A, NMDAR2B, as well as reductions in dopaminergic D1receptors and muscarinic M1 acetylcholine receptors in the hippocampus of VGLUT3–/–mice. Furthermore, mGluR2/3 total expression and mGluR5 cell surface levels were elevated in the striatum of VGLUT3–/–mice. Last, AMPAR subunit GluA1 was significantly upregulated throughout cortical, hippocampal, and striatal brain regions of VGLUT3–/–mice. Together, these findings complement and further support the evidence that VGLUT3 dynamically regulates glutamate receptor densities in several brain regions. These results suggest that VGLUT3 may play an intricate role in shaping glutamatergic signaling and plasticity in several brain areas.